Janus Henderson Group PLC decreased its holdings in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 74.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,619 shares of the biotechnology company’s stock after selling 367,679 shares during the period. Janus Henderson Group PLC owned about 0.66% of Enanta Pharmaceuticals worth $14,675,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also modified their holdings of the company. Meadow Creek Investment Management LLC bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter valued at $110,000. SG Americas Securities LLC bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter valued at $112,000. Riverhead Capital Management LLC bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter valued at $129,000. Glen Harbor Capital Management LLC bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter valued at $140,000. Finally, Sei Investments Co. lifted its stake in shares of Enanta Pharmaceuticals by 63,966.7% during the 1st quarter. Sei Investments Co. now owns 1,922 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 1,919 shares in the last quarter. 77.62% of the stock is owned by hedge funds and other institutional investors.
In other news, VP Nathalie Adda sold 4,155 shares of the business’s stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $92.32, for a total value of $383,589.60. Following the sale, the vice president now directly owns 4,465 shares in the company, valued at approximately $412,208.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jay R. Luly sold 35,000 shares of the business’s stock in a transaction dated Friday, July 6th. The stock was sold at an average price of $125.24, for a total transaction of $4,383,400.00. Following the completion of the sale, the insider now owns 625,049 shares in the company, valued at $78,281,136.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,355 shares of company stock worth $5,874,009. Corporate insiders own 10.56% of the company’s stock.
Shares of ENTA stock opened at $90.58 on Friday. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of 99.54 and a beta of 0.87. Enanta Pharmaceuticals Inc has a 52 week low of $42.49 and a 52 week high of $127.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 EPS for the quarter, missing the consensus estimate of $0.98 by ($0.01). The company had revenue of $57.26 million during the quarter, compared to analysts’ expectations of $56.59 million. Enanta Pharmaceuticals had a return on equity of 25.84% and a net margin of 37.63%. equities analysts forecast that Enanta Pharmaceuticals Inc will post 3.56 earnings per share for the current year.
ENTA has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 22nd. Oppenheimer initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, May 24th. They set a “buy” rating and a $135.00 target price on the stock. JMP Securities restated a “buy” rating and set a $120.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, July 31st. Finally, UBS Group cut shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 8th. Six equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $107.60.
Enanta Pharmaceuticals Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Story: Closed-End Mutual Funds
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.